Skip navigation
Watchlist Sponsored By :

Current DateTime: 05:44:14 28 Nov 2009
LinksList Documentid: 24355697
  • Runway Angels

      The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.

  • Smartphone Guide

      Here's a need-to-know guide to nine devices, based on features, price, network and platform.

  • Wines for the Holidays

      Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES


Current DateTime: 05:44:14 28 Nov 2009
LinksList Documentid: 33793611
  • How Well Do You Know Your Bird?

      Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.

  • A Healthier & Wealthier You

      Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.

  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?


Current DateTime: 05:44:14 28 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Crestor Competition Overshadows AstraZeneca Results
By: Reuters | 01 Nov 2007 | 08:11 AM ET
Text Size

AstraZeneca said on Thursday its blockbuster cholesterol medicine Crestor faced a generic challenge from Canada's Cobalt Pharmaceuticals, as third-quarter profits fell 14 percent.

Cobalt's application for U.S. regulatory approval to sell a copy of Crestor is a fresh blow to the Anglo-Swedish group, which is already fighting generic threats to its two biggest revenue generators, Nexium and Seroquel.

Industry analysts said Cobalt was trying to get in ahead of rival generic manufacturers and the company faced a long legal battle against the patents defending Crestor.

The news overshadowed third-quarter results from Britain's second-biggest drugmaker, which showed pre-tax profits of $1.89 billion on sales up 10 percent at $7.15 billion, equivalent to earnings per share of 91 cents -- better than some analysts had feared.

The stock fell 0.46 percent to 23.62 pounds.

The average industry analyst forecast for EPS had been 85.4 cents in a Reuters poll of 18 analysts, reflecting competition from cheap generics plus acquisition and restructuring charges.

The company said it was on track to achieve its full-year targets for underlying earnings per share in the range of $3.60 to $3.75, excluding restructuring costs and U.S. sales of heart drug Toprol XL.

Top-seller Nexium had a lacklustre quarter, reflecting pressure on the gastric acid treatment from generic omeprazole, an older medicine.

But demand was strong for schizophrenia drug Seroquel and asthma treatment Symbicort, which was launched mid-year in the United States.

Race to Challenge

AstraZeneca said it was evaluating Cobalt's allegations and had full confidence in its intellectual property. Crestor, which had sales of $691 million in the third quarter, is covered by three key patents valid until 2016, 2020 and 2021.

Mike Ward, an industry analyst at Nomura Code Securities, said the challenge did not mean sales of Crestor were in imminent danger.

Rather, it reflected the intense competition between generic drugmakers to file with the U.S. Food and Drug Administration ahead of rivals in order to gain temporary generic exclusivity.

"Across the industry, we are seeing earlier and earlier attempts to get abbreviated new drug applications into the FDA," he said.

AstraZeneca views Crestor as a key growth driver for the business in the years ahead and has been running a major clinical trials programme to try to prove its superiority to other similar statin drugs.

It originally licensed the drug from Japan's Shionogi & Co, which receives royalties on sales.

AstraZeneca stock has been under pressure year, reflecting concerns about its relatively thin pipeline of new drugs, patent threats and the poorly received deal to buy U.S. biotech firm MedImmune in April.

Many investors criticised the price tag of $15.6 billion as too high.

The shares currently trade at 12 times forecast 2008 earnings, a 15 percent discount to the European sector average.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • These four sectors will be the next to lead the market.
  • Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
  • T shirt man
  • From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
  • It may be the most unusual guide to business you'll read.
  • Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
  • "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
ADD COMMENTS
Remaining characters


Current DateTime: 01:08:03 28 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:01:49 28 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:04:29 28 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:04:29 28 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters